Investment Research and Business Due Diligence
Thursday, March 3, 2016
Ocrelizumab will be a game changer in the multiple sclerosis market
Roche is close to filing Ocrelizumab for the treatment of Multiple sclerosis in the US and EU.
Ocrelizumab has been granted breakthrough status and hence a decision can be expected by YE 2016.
Ocrelizumab may add upto $6b to Roche's annual sales by 2020.
I expect an immediate ramp up in sales for Ocrelizumab post launch because of its unique value proposition ..
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)